Myeloma | Tumor

The Latest News and Updates in Myeloma

October 27th 2020, 3:00pm


A roundup of the latest news and updates for patients with myeloma from CURE®.

Adding Darzalex to Standard Treatment for High-Risk Multiple Myeloma May Delay Disease Progression

October 27th 2020, 1:00pm


A meta-analysis of six clinical trials showed that standard treatment regimens for high-risk multiple myeloma may be more effective at delaying disease progression if they are given in combination with the targeted drug Darzalex (daratumumab).

Myeloma: The First Remission Is the Deepest

October 26th 2020, 6:00pm


Not everyone with myeloma needs to be treated right away, but when they do, there are some important upfront considerations for patients and providers.

Program Leads Patients With Cancer on ‘The Right Track’

September 24th 2020, 9:00pm


Finding the best care team can make all the difference for patients with diseases like multiple myeloma.

Drug Exposure, Disease Characteristics Not Linked to Increased Mortality Risk in Patients with Multiple Myeloma Who Contracted COVID-19

September 17th 2020, 6:00pm


Specific disease characteristics of, and treatments for, multiple myeloma were not associated with increased mortality risk in patients with multiple myeloma who developed COVID-19, according to data published in Journal of Hematology & Oncology.

Phase 3 TOURMALINE-MM2 Study Fails to Meet Primary Endpoint in Treating Newly Diagnosed Multiple Myeloma

September 14th 2020, 9:00pm


The data demonstrated that the addition of Ninlaro to Revlimid and dexamethasone led to a 13.5-month increase in median progression-free survival, compared with placebo. However, the data failed to meet the threshold for statistical significance.

Drug Conjugate Designed to Deliver Iodine-131 Shows Promise in Triple-Refractory Multiple Myeloma

September 11th 2020, 1:00pm


Forty percent of patients with triple-refractory multiple myeloma achieved a response after receiving 60 millicurie (a unit of radioactivity) or greater of CLR 131.

Velcade-Based Triplet Regimen ‘Should Remain’ Standard of Care in Newly Diagnosed Multiple Myeloma

September 10th 2020, 6:00pm


When compared with the standard of care triplet regimen of Velcade, Revlimid and dexamethasone, the combination of Kyprolis, Revlimid and dexamethasone did not demonstrate superior treatment results in patients with newly diagnosed multiple myeloma.

The Latest FDA Approvals and Updates Patients with Cancer May Have Missed

September 9th 2020, 1:00pm


There have been several drug approvals and updates from the Food and Drug Administration (FDA) in the cancer space over the last several weeks.

FDA Grants Priority Review to Melflufen-Dexamethasone Combination for Multiple Myeloma

September 4th 2020, 1:00pm


The Food and Drug Administration granted a priority review to the new drug application for melflufen in combination with dexamethasone for adults with relapsed and refractory multiple myeloma (RRMM) who had previously received multiple lines of therapy.